Oculis releases list of retina specialists and topics for R&D Retina Day on July 11, 2023


The two-hour event will share details on the company’s clinical programs for retina diseases through formal presentations and a live Q&A session.

Speaker standing in front of crowd at podium giving presentation ©kasto / adobe.stock.com

The two-hour event will share details on the company’s clinical programs for retina diseases through formal presentations and a live Q&A session.(Image Credit: Adobe Stock/kasto)

Oculis Holding AG will host its first R&D Day on July 11, 2023 from 10:00 am to 12:00 pm EDT. This two-hour event is designed to showcase the company’s clinical programs and will feature several retina experts to discuss how these programs could impact the retina diseases they are targeting. Virtual registration is available for those interested in attending.1

The Oculis management team will be joined by retina specialists to discuss the unmet medical needs and current treatment landscapes of Diabetic Macular Edema (DME), Cystoid Macular Edema (CME), and Acute Optic Neuritis (AON). They also plan to share insights on the following programs:

  • OCS-01 DME DIAMOND program: The recent Stage 1 read-out of the DIAMOND trial and plans for the upcoming DIAMOND 1 and DIAMOND 2 trials
  • OCS-01 CME LEOPARD trial: The PoC LEOPARD trial initiation of OCS-01 eye drops in CME
  • OCS-05 AON ACUITY trial: The ongoing PoC ACUITY trial of OCS-05, a neuroprotective candidate with a novel mechanism of action, in Acute Optic Neuritis

The retina experts participating includes:

  • Sophie Bonnin, MD: Neuro-retina specialist at the Foundation Rothschild Hospital, Paris, with clinical expertise in retina, neuro-ophthalmology and clinical imaging
  • David S. Boyer, MD: Co-principal investigator of the DIAMOND trial; Partner, Retina Vitreous Associates Medical Group; Adjunct Clinical Professor of Ophthalmology at the University of Southern California Keck School of Medicine; Oculis Scientific Advisory Board (SAB) member
  • Quan Dong Nguyen, MD, MSc, FARVO, FASRS: Principal investigator of the LEOPARD trial; Oculis SAB member; Professor of Ophthalmology at the Byers Eye Institute, Stanford University School of Medicine
  • Arshad M. Khanani, MD, MA, FASRS: Co-principal investigator of the DIAMOND trial; Oculis SAB member; Managing Partner, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates; Clinical Associate Professor at the University of Nevada, Reno School of Medicine

Following formal presentations, there will be a live and online question and answer (Q&A) session with the retina specialists, Oculis management, and additional expert panelists. The Q&A session will be facilitated by Oculis’s CEO, Riad Sherif, MD, while Bastian Dehmel, MD, Head of Development, will be available to answer questions. The additional expert panelists joining in the Q&A session include:

  • Pravin Dugel, MD: Oculis Board of Directors member, retina specialist, and President of Iveric Bio. Prior to Iveric Bio, Dr. Dugel was Managing Partner, Retinal Consultants of Arizona and the Retinal Research Institute; Clinical Professor, USC Eye Institute, Keck School of Medicine, University of Southern California
  • Sabri Markabi, MD: Independent R&D consultant with 25 years of senior and worldwide leadership experience in drug development executive roles including Global Head of Research and Development & Chief Medical Officer at Alcon and Global Head of Development for the Ophthalmology and Neuroscience Franchises at Novartis; Oculis Scientific Advisory Board (SAB) member
  • Ramin Tadayoni, MD: Professor of Ophthalmology at University of Paris; Head of the Department of Ophthalmology at Lariboisière University Hospital and at the Foundation Rothschild Hospital; Retina Chair of Oculis SAB
  • Pablo Villoslada, MD: Adjunct Professor at Stanford University; former Medical Director of Neuroinflammation at Genentech; Oculis SAB member

Event registration can be found at https://lifescievents.com/event/oculis/.

  1. Oculis to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases on Tuesday, July 11, 2023. Oculis SA. June 26, 2023. Accessed June 26, 2023. https://www.globenewswire.com/news-release/2023/06/26/2694396/0/en/Oculis-to-Host-an-R-D-Retina-Day-to-Showcase-Clinical-Programs-Targeting-Diabetic-Macular-Edema-and-Other-Retina-Diseases-on-Tuesday-July-11-2023.html
Related Videos
Video 4 - "Treating Geographic Atrophy in Patients with Concurrent Neovascular AMD"
Video 3 - "Managing a Patient with Bilateral Geographic Atrophy"
Video 2 - "FDA-approved Therapies for Geographic Atrophy"
Video 1 - "Geographic Atrophy: Overview, Diagnosis, and Progression"
Marion Munk, MD, PhD, presenting slides
Marion Munk, MD, PhD, presenting slides
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
© 2024 MJH Life Sciences

All rights reserved.